U.S. markets open in 2 hours 10 minutes
  • S&P Futures

    3,667.50
    +0.25 (+0.01%)
     
  • Dow Futures

    29,855.00
    -13.00 (-0.04%)
     
  • Nasdaq Futures

    12,484.25
    +30.00 (+0.24%)
     
  • Russell 2000 Futures

    1,836.30
    -1.20 (-0.07%)
     
  • Crude Oil

    44.93
    -0.35 (-0.77%)
     
  • Gold

    1,845.40
    +15.20 (+0.83%)
     
  • Silver

    24.36
    +0.28 (+1.18%)
     
  • EUR/USD

    1.2136
    +0.0021 (+0.17%)
     
  • 10-Yr Bond

    0.9480
    0.0000 (0.00%)
     
  • Vix

    20.94
    +0.17 (+0.82%)
     
  • GBP/USD

    1.3448
    +0.0072 (+0.54%)
     
  • USD/JPY

    104.2600
    -0.1640 (-0.16%)
     
  • BTC-USD

    19,309.24
    +359.99 (+1.90%)
     
  • CMC Crypto 200

    379.54
    +14.62 (+4.01%)
     
  • FTSE 100

    6,471.49
    +8.10 (+0.13%)
     
  • Nikkei 225

    26,809.37
    +8.39 (+0.03%)
     

Protagonist Therapeutics to Participate in the Jefferies Virtual 2020 London Healthcare Conference

·2 min read

NEWARK, Calif., Nov. 11, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies Virtual 2020 London Healthcare Conference.

Presentation details:
Date: Tuesday, Nov. 17, 2020
Time: 5:35 p.m. GMT (12:35 p.m. EST)

A live and archived webcast of the event will be available at https://wsw.com/webcast/jeff141/ptgx/1873875 and in the Investors section of the Protagonist Therapeutics website at http://investors.protagonist-inc.com/.

About Protagonist Therapeutics, Inc.

Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based therapeutics to address significant unmet medical needs and transform existing treatment paradigms for patients. The Company currently has three clinical-stage assets. PTG-300 is an injectable hepcidin mimetic in development for the treatment of polycythemia vera and other blood disorders. PTG-200 is an orally delivered, gut-restricted, interleukin-23 receptor specific antagonist peptide in development for the treatment of inflammatory bowel disease, with Crohn's disease as the initial indication. In addition to PTG-200, two oral peptide interleukin-23 receptor antagonist candidates from a collaboration with Janssen Biotech, Inc., are in development and have been selected for advancement into clinical studies. PN-943 is an orally delivered, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide in development for the treatment of inflammatory bowel disease, with ulcerative colitis as the initial targeted indication.

Protagonist is headquartered in Newark, California. For further information, please visit http://www.protagonist-inc.com.

Cision
Cision

View original content:http://www.prnewswire.com/news-releases/protagonist-therapeutics-to-participate-in-the-jefferies-virtual-2020-london-healthcare-conference-301171288.html

SOURCE Protagonist Therapeutics, Inc.